QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients-Reference-Cited by-同舟云学术

QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients

Published:2016-02-25 Issue:4 Volume:263 Page:784-791
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Ziemssen Tjalf,Calabrese Pasquale,Penner Iris-Katharina,Apfel Rainer

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-016-8058-7.pdf

Reference24 articles.

1. Johnson KP (2010) Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag 6:153–172

2. Zwibel H, Smrtka J (2011) Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 17:S139–S145

3. Krause I, Kern S, Horntrich A, Ziemssen T (2013) Employment status in multiple. Mult Scler 19(13):1792–1799

4. Ziemssen T (2009) Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 227(suppl 1):S37–S41

5. Freal JE, Kraft GH, Coryell JK (1984) Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 65(3):135–138

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Quality of reporting health behaviors for multiple sclerosis (QuoRH‐MS): A scoping review to inform intervention planning and improve consistency of reporting;Brain and Behavior;2024-08

3. Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review;Brain Sciences;2023-12-20

4. The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review;Frontiers in Neurology;2023-07-12

5. Copolímero-1 como terapia potencial para el deterioro cognitivo leve;Neurología, Neurocirugía y Psiquiatría;2023